First indication of PBA-0405 activity in patient settings
Pure Biologics released first biomarker data obtained in Phase O clinical study in Head and Neck patients receiving intra-tumoral injection of PBA-0405.
Early results indicate that in the two out of three patient markers for tumor cell killing are increased near PBA-0405 injection sites in comparison to control injections (vehicle).
PBA-0405 is a fully human monoclonal antibody developed to treat solid tumors and B-cell malignancies by targeting ROR1, a protein expressed highly on many cancers but have a restricted expression in healthy tissues. PBA-0405 is optimized for ability to induce immune cell-mediated tumor cell death by afucosylation and optimized epitope in contrast to other anti-ROR1 antibodies such as zilovertamab that blocks proliferation and migration of ROR1 positive cells.
Pure Biologics